<?xml version="1.0" encoding="UTF-8"?>
<p id="Par68">The interaction between the SARS viruses and ACE2 has been proposed as a potential factor in their infectivity, and there are concerns about the use of RAAS inhibitors that may alter ACE2 and whether variation in ACE2 expression may be in part responsible for disease virulence in the ongoing COVID-19 pandemic [
 <xref ref-type="bibr" rid="CR56">56</xref>, 
 <xref ref-type="bibr" rid="CR57">57</xref>]. Clinical trials are under way to test the safety and efficacy of RAAS modulators, including recombinant human ACE2 (n016) [
 <xref ref-type="bibr" rid="CR58">58</xref>, 
 <xref ref-type="bibr" rid="CR59">59</xref>].
</p>
